Skip to Content
Merck
All Photos(1)

Key Documents

261149

Sigma-Aldrich

Lutetium

ingot, 99.9% trace rare earth metals basis

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
Lu
CAS Number:
Molecular Weight:
174.97
EC Number:
MDL number:
UNSPSC Code:
12352300
PubChem Substance ID:

Quality Level

Assay

99.9% trace rare earth metals basis

form

ingot

reaction suitability

reagent type: catalyst
core: lutetium

resistivity

54 μΩ-cm, 20°C

bp

3402 °C (lit.)

mp

1663 °C (lit.)

density

9.84 g/mL at 25 °C (lit.)

SMILES string

[Lu]

InChI

1S/Lu

InChI key

OHSVLFRHMCKCQY-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Pictograms

Flame

Signal Word

Danger

Hazard Statements

Precautionary Statements

Hazard Classifications

Flam. Sol. 1

Storage Class Code

4.1B - Flammable solid hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Xuejuan Wang et al.
European journal of nuclear medicine and molecular imaging, 39(12), 1876-1885 (2012-08-29)
Targeting of tumours positive for somatostatin receptors (sst) with radiolabelled peptides is of interest for tumour localization, staging, therapy follow-up and targeted radionuclide therapy. The peptides used clinically are exclusively agonists, but recently we have shown that the radiolabelled somatostatin-based
S Shcherbinin et al.
Physics in medicine and biology, 57(18), 5733-5747 (2012-09-06)
We investigated the quantitative accuracy of SPECT/CT imaging studies as would be performed before and after targeted radionuclide therapy (TRT) using phantom experiments with (i) (99m)Tc, (ii) ¹⁷⁷Lu and (iii) ⁹⁰Y/¹⁷⁷Lu. While the experiment with (99m)Tc imitated a diagnostic scan
Arnaud Dieudonné et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(2), 236-243 (2012-12-20)
Dose kernel convolution (DK) methods have been proposed to speed up absorbed dose calculations in molecular radionuclide therapy. Our aim was to evaluate the impact of tissue density heterogeneities (TDH) on dosimetry when using a DK method and to propose
Rebecca A Dumont et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(5), 762-769 (2013-03-16)
The gastrin-releasing peptide receptor (GRPr) is overexpressed in prostate cancer and is an attractive target for radionuclide therapy. In addition, inhibition of the protein kinase mammalian target of rapamycin (mTOR) has been shown to sensitize various cancer cells to the
Jostein Dahle et al.
Anticancer research, 33(1), 85-95 (2012-12-26)
The monoclonal antibody against CD20, rituximab, alone, or as part of combination therapies, is standard therapy for non-Hodgkin's B-cell lymphoma. Despite significantly better clinical results obtained for beta-emitting radioimmunoconjugates (RICs), RICs targeting CD20 are not commonly used in medical practice

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service